IFNβ bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays

Journal of Neuroimmunology

Volumn 189, Issue 1-2, 2007, Pages 102-110

  Capra, Ruggero ^a   Sottini, Alessandra ^a   Cordioli, Cinzia ^a   Serana, Federico ^a   Chiarini, Marco ^a   Caimi, Luigi ^a   Padovani, Alessandro ^b   Bergamaschi, Roberto ^c   Imberti, Luisa ^a  

^a SPEDALI CIVILI   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

BAbs; Bioavailability; Interferons; Multiple sclerosis; MxA; NAbs

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; INTERFERON BETA SERINE; MESSENGER RNA; MYXOVIRUS RESISTANCE PROTEIN A; NEUTRALIZING ANTIBODY; ANTIBODY; GUANINE NUCLEOTIDE BINDING PROTEIN; MYXOVIRUS RESISTANCE PROTEINS; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BIOAVAILABILITY; DRUG MECHANISM; FEMALE; GENE EXPRESSION; GENE INDUCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RADIOIMMUNOPRECIPITATION; RELIABILITY; BIOAVAILABILITY; BIOSYNTHESIS; CLINICAL TRIAL; GENETICS; IMMUNOLOGY; IMMUNOPRECIPITATION; METABOLISM; METHODOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; RADIOIMMUNOASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; ANTIBODIES; BIOLOGICAL AVAILABILITY; FEMALE; GTP-BINDING PROTEINS; HUMANS; IMMUNOPRECIPITATION; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RADIOIMMUNOASSAY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STATISTICS, NONPARAMETRIC;

EID: 34548590673     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2007.06.006     Document Type: Article

References (36)

1. Bendtzen K. Anti-IFN BAb and NAb antibodies: a minireview. Neurology 61 (2003) S6-S10
2. Bertolotto A., Malucchi S., Milano E., Castello A., Capobianco M., and Mutani R. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 48 (2000) 95-100
3. Bertolotto A., Gilli F., Sala A., Audano L., Castello A., Magliola U., Melis F., and Giordana M.T. Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J. Immunol. Methods 256 (2001) 141-152
4. Brickelmaier M., Hochman P.S., Baciu R., Chao B., Cuervo J.H., and Whitty A. ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-beta. J. Immunol. Methods 227 (1999) 121-135
5. Chieux V., Hober D., Harvey J., Lion G., Lucidarme D., Forzy G., Duhamel M., Cousin J., Ducoulombier H., and Wattre P. The MxA protein levels in whole blood lysates of patients with various viral infections. J. Virol. Methods 70 (1998) 183-191
6. Clanet M., Kappos L., Hartung H.P., and Hohlfeld R. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study. Mult. Scler. 10 (2004) 139-144
7. Deisenhammer F., Mayringer I., Harvey J., Dilitz E., Gasse T., Stadlbauer D., Reindl M., and Berger T. A comparative study of the relative bioavailability of different interferon beta preparations. Neurology 54 (2000) 2055-2060
8. Deisenhammer F., Reindl M., and Berger T. Immunoglobulin subclasses in patients with neutralizing and nonneutralizing antibodies against IFN-beta1b. J. Interferon Cytokine Res. 21 (2001) 167-171
9. Gilli F., Marnetto F., Caldano M., Sala A., Malucchi S., Di Sapio A., Capobianco M., and Bertolotto A. Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis. J. Neuroimmunol. 158 (2005) 195-203
10. Gilli F., Marnetto F., Caldano M., Sala A., Malucchi S., Capobianco M., and Bertolotto A. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult. Scler. 12 (2006) 47-57
11. Giovannoni G., Munschauer III F.E., and Deisenhammer F. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 73 (2002) 465-469
12. Grossberg S.E., Kawade Y., Kohase M., and Klein J.P. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J. Interferon Cytokine Res. 21 (2001) 743-755
13. Hemmer B., Stuve O., Kieseier B., Schellekens H., and Hartung H.P. Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol. 4 (2005) 403-412
14. IFNB Multiple Sclerosis Study Group, and University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 47 (1996) 889-894
15. Kappos L., Clanet M., Sandberg-Wollheim M., Radue E.W., Hartung H.P., Hohlfeld R., Xu J., Bennett D., Sandrock A., and Goelz S. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 65 (2005) 40-47
16. Larocca A.P., Leung S.C., Marcus S.G., Colby C.B., and Borden E.C. Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser. J. Interf. Res. 1 (1989) S51-S60
17. Lawrence N., Oger J., Aziz T., Palace J., and Vincent A. A sensitive radioimmunoprecipitation assay for assessing the clinical relevance of antibodies to IFN beta. J. Neurol. Neurosurg. Psychiatry 74 (2003) 1236-1239
18. Malucchi S., Sala A., Gilli F., Bottero R., Di Sapio A., Capobianco M., and Bertolotto A. Neutralizing antibodies reduce the efficacy of beta IFN during treatment of multiple sclerosis. Neurology 62 (2004) 2031-2037
19. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., and Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50 (2001) 121-127
20. McKay F., Schibeci S., Heard R., Stewart G., and Booth D. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort. J. Immunol. Methods 310 (2006) 20-29
21. Pachner A.R. An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients. Neurology 61 (2003) 1444-1446
22. Pachner A.R. Anti-IFNbeta antibodies in IFNbeta-treated MS patients. Neurology 61 (2003) S1-S5
23. Pachner A.R., Narayan K., Price N., Hurd M., and Dail D. MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol. Diagn. 7 (2003) 17-25
24. Pachner A.R., Oger J., and Palace J. The measurement of antibodies binding to IFNbeta in MS patients treated with IFNbeta. Neurology 61 (2003) S18-S20
25. Pachner A.R., Dail D., Pak E., and Narayan K. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. J. Neuroimmunol. 166 (2005) 180-188
26. Pachner A.R., Narayan K., and Pak E. Multiplex analysis of expression of three IFNbeta-induced genes in antibody-positive MS patients. Neurology 66 (2006) 444-446
27. Polman C., Kappos L., White R., Dahlke F., Beckmann K., Pozzilli C., Thompson A., Petkau J., Miller D., and European Study Group in Interferon Beta-1b in Secondary Progressive MS. Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 60 (2003) 37-43
28. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352 (1998) 1498-1504
29. Ramsden S.C., Daly S., Geilenkeuser W.J., Duncan G., Hermitte F., Marubini E., Neumaier M., Orlando C., Palicka V., Paradiso A., Pazzagli M., Pizzamiglio S., and Verderio P. EQUAL-quant: an international external quality assessment scheme for real-time PCR. Clin. Chem. 52 (2006) 1584-1591
30. Ross C., Clemmesen K.M., Svenson M., Sorensen P.S., Koch-Henriksen N., Skovgaard G.L., and Bendtzen K. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann. Neurol. 48 (2000) 706-712
31. Ross C., Clemmesen K.M., Sorensen P.S., Koch-Henriksen N., and Bendtzen K. Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis. Mult. Scler. 12 (2006) 39-46
32. Rudick R.A., Simonian N.A., Alam J.A., Campion M., Scaramucci J.O., Jones W., Coats M.E., Goodkin D.E., Weinstock-Guttman B., Herndon R.M., Mass M.K., Richert J.R., Salazar A.M., Munschauer III F.E., Cookfair D.L., Simon J.H., and Jacobs L.D. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 50 (1998) 1266-1272
33. Runkel L., Meier W., Pepinsky R.B., Karpusas M., Whitty A., Kimball K., Brickelmaier M., Muldowney C., Jones W., and Goelz S.E. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm. Res. 15 (1998) 641-649
34. Sorensen P.S., Deisenhammer F., Duda P., Hohlfeld R., Myhr K.M., Palace J., Polman C., Pozzilli C., Ross C., and EFNS Task Force on Anti-IFN-beta Antibodies in Multiple Sclerosis. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur. J. Neurol. 12 (2005) 817-827
35. Sorensen P.S., Koch-Henriksen N., Ross C., Clemmesen K.M., Bendtzen K., and Danish Multiple Sclerosis Study Group. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 65 (2005) 33-39
36. Vallittu A.M., Halminen M., Peltoniemi J., Ilonen J., Julkunen I., Salmi A., Eralinna J.P., and Finnish Beta-Interferon Study Group. Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients. Neurology 58 (2002) 1786-1790